Amgen
Develops and manufactures medicines and biosimilars across general medicine, rare disease, inflammation, and oncology.
$430.27
After-hours close−2.11 (−0.49%)
At close$432.38(−1.05%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $5.79 | — | — |
| Aug 2026 | $5.62 | $6.29 | +11.9% |
| Apr 2026 | $4.77 | $5.15 | +8.0% |
| Feb 2026 | $4.73 | $5.29 | +11.8% |
| Nov 2025 | $5.02 | $5.64 | +12.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Jan 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | $5.79 | — | — | $10.05B | — | — |
| Aug 4, 2026 | $5.62 | $6.29 | +11.9% | $9.43B | $10.05B | +6.7% |
| Apr 30, 2026 | $4.77 | $5.15 | +8.0% | $8.58B | $8.62B | +0.5% |
| Feb 3, 2026 | $4.73 | $5.29 | +11.8% | $9.47B | $9.87B | +4.1% |
| Nov 4, 2025 | $5.02 | $5.64 | +12.4% | $8.97B | $9.56B | +6.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 5, 2025 | ||||||
| May 1, 2025 | ||||||
| Feb 4, 2025 | ||||||
| Oct 30, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 6, 2024 | ||||||
| Oct 31, 2023 | ||||||
| Aug 3, 2023 | ||||||
| Apr 27, 2023 | ||||||
| Jan 31, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| Apr 27, 2022 | ||||||
| Feb 7, 2022 | ||||||
| Nov 2, 2021 | ||||||
| Aug 3, 2021 | ||||||
| Apr 27, 2021 | ||||||
| Feb 2, 2021 | ||||||
| Oct 28, 2020 | ||||||
| Jul 28, 2020 | ||||||
| Apr 30, 2020 | ||||||
| Jan 30, 2020 | ||||||
| Oct 29, 2019 | ||||||
| Jul 30, 2019 | ||||||
| Apr 30, 2019 | ||||||
| Jan 29, 2019 | ||||||
| Oct 30, 2018 | ||||||
| Jul 26, 2018 | ||||||
| Apr 24, 2018 | ||||||
| Feb 1, 2018 | ||||||
| Oct 25, 2017 | ||||||
| Jul 25, 2017 | ||||||
| Apr 26, 2017 | ||||||
| Feb 2, 2017 | ||||||
| Oct 27, 2016 | ||||||
| Jul 27, 2016 | ||||||
| Apr 28, 2016 | ||||||
| Jan 28, 2016 | ||||||
| Oct 28, 2015 | ||||||
| Jul 30, 2015 | ||||||